To recover your password please fill in your email address
Please fill in below form to create an account with us
A randomized phase III trial comparing conventional-dose chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with high-dose chemotherapy using mobilizing Paclitaxel plus Ifosfamide followed by high-dose Carboplatin and Etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors (ANZUP1604).
See ANZCTR for full trial details >
|
Trial Summary: |
To compare the overall survival in patients treated with conventional-dose chemotherapy using TIP regimen with high-dose chemotherapy plus autologous stem cell transplant using TI-CE regimen as initial salvage treatment of patients with relapsed or refractory germ cell tumours. |
|
Supported By: |
The Movember Foundation |
|
Eligibility: |
Men aged ≥14 years with evidence of progressive or recurrent germ cell tumours (both seminoma and nonseminoma) and have previously received 3-6 cycles of cisplatin-based chemotherapy as part of first-line chemotherapy. |
|
Registration ID: |
ACTRN12618001236280 |
|
Participation: |
International |
|
Australian Lead Group: |
ANZUP |
|
Status: |
In follow-up |
|
Activation Date: |
2nd March 2018 |
|
Chairs: |
A/Prof Peter Grimison |
|
Contact: |